Table 1:
Biologic | Primary analysis: adjustment factor, % | Policy consideration #1: include insulin glargine, % | Policy consideration #2: include biosimilar for adalimumab, % | Policy consideration #3: negotiated price reductions below threshold, % |
---|---|---|---|---|
Etanercept | 62.0 | 62.8 | 62.8 | 75, 50 |
Infliximab | 53.2 | 53.2 | 53.2 | 75, 50 |
Adalimumab | NA | NA | 60.0 | 75, 50 |
Insulin glargine | NA | 75.0 | NA | NA |
Note: NA = not applicable.